Investigating Big Pharma Licensing Trends
AstraZeneca’s Licensing Tactics Make It Top Dealmaker
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.
You may also be interested in...
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.